Vinci Pharmaceuticals Inc., a New Jersey-based specialty ophthalmic pharmaceutical company, has closed a Series A financing round exceeding $8 million to advance EPIPLANT, its investigational sustained-release drug delivery platform designed to deliver medicines to retinal tissues without repeated injections directly into the eye. Announced on October 8, 2026, the investment was led by Dynagrow Capital, LLLP, with support from MintPharma Capital, and will fund manufacturing and quality-control activities for the company’s VCI-002 product ahead of a planned first-in-human Phase 1/2a clinical study in 2027.
The financing brings Vinci Pharmaceuticals’ disclosed capital to more than $16.5 million, including an earlier $8.5 million seed financing round, excluding interest on convertible notes. The company intends to use the new investment for Good Manufacturing Practice manufacturing, product testing and release activities, establishing the material and quality systems needed to progress EPIPLANT VCI-002 towards clinical investigation.
EPIPLANT is designed as a bioerodible episcleral implant that releases small-molecule medicines over time. Unlike intravitreal injections, which introduce a treatment directly into the eye’s vitreous cavity, the episcleral approach places a drug-delivery system against the outer surface of the sclera, potentially allowing medication to reach retinal tissues through a different anatomical pathway.
The approach addresses a persistent difficulty in retinal disease management: treatments may be effective under controlled clinical conditions but require repeated administration, monitoring and specialist appointments to maintain their benefits. A sustained-release implant capable of maintaining appropriate retinal drug concentrations could reduce some of that treatment burden, although the proposed advantages remain unproven in humans for EPIPLANT.
The funding therefore represents a development milestone rather than a clinical breakthrough. Vinci Pharmaceuticals has reported preliminary preclinical testing and intellectual property protection for its technology, but it has not disclosed human efficacy results, an approved product or a completed clinical trial demonstrating the duration and consistency of drug delivery.
Why is Vinci Pharmaceuticals using the $8 million Series A round to prioritise manufacturing and clinical readiness?
The allocation of the new capital indicates that Vinci Pharmaceuticals is moving from preliminary development towards the practical requirements of testing a manufactured ophthalmic product in humans. The company has identified Good Manufacturing Practice production, testing and release of VCI-002 as immediate priorities, alongside preparation for the Phase 1/2a study. These activities are essential for establishing whether an implant can be produced consistently with suitable quality, stability and drug-release characteristics.
The financing was led by Dynagrow Capital, with participation from MintPharma Capital, reflecting continued investor support for the company’s delivery technology. Philip A. Gioia, co-founder, chairman and chief executive officer of Vinci Pharmaceuticals, indicated that the investment would support preparations for initial clinical testing and the company’s objective of reducing the burden associated with conventional retinal treatment. Dynagrow Capital Managing Director Sarah Hassan identified the potential to extend treatment intervals as part of the investment rationale, although no clinical evidence establishing improved adherence has yet been disclosed.
The financial details also require careful interpretation. Vinci Pharmaceuticals has not disclosed its post-financing valuation, investor ownership percentages, securities issued or a detailed allocation of expenditure across manufacturing and clinical activities. The aggregate funding of more than $16.5 million represents capital secured across the disclosed financing rounds, not necessarily the amount of cash currently available for future development.
The new financing strengthens the company’s ability to pursue its next development milestone, but it does not establish sufficient funding for later-stage clinical trials or commercial manufacturing. Ophthalmic development programmes can require substantial additional investment as studies expand and regulatory evidence requirements increase. Vinci’s future financing needs will depend on the results of its initial study, manufacturing progress and the scope of subsequent development.
How does EPIPLANT deliver retinal medication differently from conventional intravitreal injections?
EPIPLANT is based on an episcleral delivery approach, meaning the implant is positioned against the sclera, the tough outer covering of the eye. Its intended function is to release an incorporated medicine gradually, allowing the active substance to move towards the retinal tissues where treatment is needed. The company describes the platform as bioerodible, indicating that its design involves material intended to degrade over time rather than remain permanently unchanged.
The technology originated in the laboratory of Karl Csaky, a retinal disease researcher associated with the Retina Foundation of the Southwest in Dallas, Texas. Vinci Pharmaceuticals has licensed the technology from the foundation and reported obtaining multiple patents covering its proprietary platform. The licensing arrangement establishes the company’s development rights, although the announcement does not disclose the financial terms, territorial scope or remaining patent life.
One potential advantage is avoiding repeated administration of medication directly into the vitreous cavity. Intravitreal injections are widely used because they can deliver established therapies to the posterior segment of the eye, but they require repeated procedures and ongoing clinical appointments. An implant releasing medication over an extended period could potentially reduce the frequency of those interventions if it achieves adequate and sustained drug exposure.
However, the description of EPIPLANT as needle-free needs to be understood in its anatomical and procedural context. Avoiding an intravitreal needle does not necessarily mean implantation is non-invasive or requires no procedure. The eventual administration technique, placement requirements and associated risks will need to be established through the product’s clinical development programme.
The route also creates a different pharmacological challenge. Medication released outside the sclera must cross several ocular tissue barriers before reaching its intended retinal location, while local blood circulation can remove part of the administered drug. The success of EPIPLANT will depend on achieving sufficient exposure in the target tissues without excessive distribution elsewhere in the eye or systemic circulation.
Why could sustained-release episcleral implants help address treatment burden in retinal diseases?
Long-term treatment requirements remain an important consideration in diseases such as diabetic macular edema and neovascular age-related macular degeneration. Many patients receive medicines that inhibit vascular endothelial growth factor, a signalling protein involved in abnormal blood vessel growth and vascular leakage. These treatments can preserve or improve vision, but maintaining disease control often requires repeated injections and monitoring over extended periods.
The treatment burden extends beyond the injection itself. Patients may need transportation, time away from work, assistance from caregivers and repeated specialist appointments, particularly when mobility or visual impairment makes independent travel difficult. Missed appointments or treatment interruption can be associated with poorer outcomes in diseases requiring continued suppression of pathological activity.
A sustained-release platform could reduce some of these difficulties if it provides a sufficiently long duration of action. However, treatment durability must be measured through actual pharmacological activity and clinical outcomes rather than assumed from the presence of an implant. Releasing medication continuously does not automatically guarantee that therapeutically effective concentrations will be maintained in the retina.
The distinction is particularly relevant because modern retinal treatment already includes longer-acting pharmaceutical formulations and treatment schedules that can extend intervals between injections in appropriately selected patients. Vinci Pharmaceuticals will therefore need to demonstrate value beyond the general proposition that fewer interventions are desirable. The relevant comparison will involve clinical efficacy, treatment duration, safety and practical administration requirements.
EPIPLANT could also have potential applications where locally delivered small molecules offer mechanisms different from the biological therapies currently used in some retinal diseases. However, the company’s initial announcement does not establish which therapeutic mechanisms will be pursued across its future programmes. The broader platform opportunity remains dependent on successfully pairing particular medicines with the delivery technology.
What are the main scientific challenges facing sustained drug delivery through the sclera?
The anatomical barriers involved in transscleral drug delivery are well recognised in ophthalmic research. Medicines released at the episcleral surface must move through or around tissues including the sclera, choroid and retinal pigment epithelium, depending on the desired target. Drug movement can be influenced by molecular size, solubility, tissue binding and the biological characteristics of the surrounding ocular structures.
The choroid presents a particularly important challenge because its extensive blood supply can remove medication before sufficient concentrations reach deeper retinal tissues. Research examining alternative routes of ocular drug administration has repeatedly identified vascular clearance and tissue permeability as factors limiting the efficiency of posterior-segment delivery. These considerations are especially relevant when attempting to maintain drug exposure over weeks or months.
Earlier experimental research has demonstrated that episcleral systems can release drugs over prolonged periods, but successful release from an implant does not necessarily translate into adequate drug concentrations at the intended tissue. The relationship between release rate, ocular distribution and pharmacological activity therefore needs to be established for each medicine and formulation. Results obtained with one compound cannot automatically be extended to another because their physicochemical properties may differ substantially.
EPIPLANT’s proposed bioerodible design introduces additional technical considerations. The breakdown of the implant material must be compatible with ocular tissues, and degradation should not create unacceptable inflammation or interfere with drug-release consistency. Manufacturing controls must also ensure that the material behaves predictably throughout the intended administration period.
Vinci Pharmaceuticals has reported completing preliminary preclinical testing but has not published a detailed VCI-002 dataset in the financing announcement. Quantitative retinal drug concentrations, duration of release, tissue distribution and product-specific safety results were not disclosed. These measurements will be important for assessing whether the technology can overcome the delivery limitations identified in earlier transscleral research.
What is known about VCI-002 and its planned Phase 1/2a clinical study in 2027?
VCI-002 is the EPIPLANT-based product identified for advancement using the Series A proceeds. Vinci Pharmaceuticals expects to initiate its first human Phase 1/2a study during 2027, following manufacturing, testing and release preparations. The proposed programme marks a transition towards evaluating the delivery platform in a clinical setting, although the trial has not been described as underway.
The October announcement does not identify the active pharmaceutical ingredient incorporated into VCI-002 or specify its initial disease indication. Nor does it disclose the intended dose, expected duration of drug release, enrolment target, participating clinical sites or detailed primary and secondary endpoints. These details will be necessary for interpreting the programme’s clinical objectives once the study design is formally established.
Vinci Pharmaceuticals identifies diabetic macular edema and intermediate age-related macular degeneration among the broader markets it hopes to address through its pipeline. However, those strategic interests do not establish that VCI-002 will be tested in both conditions or that the product has a confirmed indication covering either disease. The identity and characteristics of the active ingredient will be important in determining the clinical population and appropriate measures of treatment response.
An early ophthalmic study would be expected to assess safety and tolerability, alongside relevant measures of ocular exposure and preliminary clinical activity where feasible. Depending on the selected indication, investigators may examine visual acuity, retinal anatomy through optical coherence tomography, inflammation or other disease-specific measurements. Those possibilities remain development considerations rather than confirmed endpoints for the planned VCI-002 trial.
The regulatory pathway will also depend on the final product configuration, intended therapeutic use and supporting manufacturing and preclinical evidence. The announcement does not establish that VCI-002 has received FDA marketing approval or that the company has secured authorisation to begin its proposed human investigation. Preparing for a first-in-human study is therefore distinct from having completed the regulatory requirements necessary to enrol patients.
How does EPIPLANT compare with existing long-acting retinal treatment technologies?
The commercial opportunity for sustained retinal drug delivery is supported by the development of technologies intended to extend treatment intervals. One established example is Susvimo, the ranibizumab ocular implant marketed by Genentech, a member of the Roche Group. The FDA-approved system provides continuous delivery of an anti-VEGF medicine through an implanted reservoir, with refill intervals determined by the authorised disease indication.
For neovascular age-related macular degeneration and diabetic macular edema, the approved Susvimo dosing schedule includes refill-exchange procedures approximately every six months. The system has demonstrated that sustained intraocular treatment can become a regulated commercial option, but its surgical requirements and safety profile remain important considerations. Its prescribing information includes a boxed warning concerning endophthalmitis, illustrating that reducing injection frequency does not eliminate procedure-related risks.
EPIPLANT differs by seeking to deliver medicine from an episcleral location rather than through a reservoir placed for intravitreal drug delivery. Vinci’s current platform is intended for small molecules and uses a bioerodible implant design, creating a different delivery concept from a refillable ocular reservoir. These distinctions may influence manufacturing, administration, drug selection and the types of retinal diseases the platform could eventually address.
However, differences in technology do not establish superior safety or efficacy. Susvimo’s clinical performance and regulatory status are supported by human studies, while EPIPLANT has not yet generated disclosed human data. Comparing treatment intervals or clinical outcomes between the products would therefore be premature.
Vinci Pharmaceuticals must also consider the progress of pharmaceutical treatments that extend injection intervals without requiring a separate implanted delivery system. Such advances influence the level of convenience and clinical benefit that a new platform would need to demonstrate. EPIPLANT’s eventual positioning will depend on the specific medicine it delivers and the evidence supporting its use in a defined patient population.
Why will GMP manufacturing and quality control be central to the VCI-002 programme?
The decision to direct Series A proceeds towards Good Manufacturing Practice activities reflects the requirements associated with developing a product that combines drug delivery with an implanted material. The formulation must contain a defined quantity of active pharmaceutical ingredient, maintain appropriate stability and release that ingredient within an acceptable range. Differences in manufacturing conditions could affect the rate or duration of medication exposure.
Quality testing may need to address drug content, release characteristics, sterility, material properties and other product-specific attributes. Bioerodible implants introduce additional considerations relating to degradation behaviour and the potential impact of manufacturing variability on implant performance. The appropriate testing programme will depend on the final formulation and regulatory requirements.
Manufacturing readiness also affects the reliability of clinical evidence. If implants used in different study cohorts vary substantially in drug content or release performance, interpreting clinical responses becomes more difficult. Establishing consistent product characteristics before the first study therefore provides a foundation for meaningful safety and pharmacological assessment.
Vinci Pharmaceuticals has not announced that commercial-scale production of VCI-002 has begun or that manufacturing validation has been completed. The financing is intended to support progress towards clinical-supply readiness rather than an immediate commercial launch. Later-stage development would likely require additional process qualification, stability information and scale-up activities.
Could the EPIPLANT platform create opportunities beyond a single retinal therapy?
One of Vinci Pharmaceuticals’ central commercial propositions is that EPIPLANT could accommodate different small-molecule active pharmaceutical ingredients. If demonstrated, this flexibility could allow the company to develop multiple products addressing different retinal disease mechanisms without designing an entirely new delivery platform for each programme. However, the performance of each formulation would still need to be independently evaluated.
Different medicines may require substantially different exposure levels and release profiles to produce an appropriate therapeutic response. A formulation suitable for one retinal indication may not provide sufficient concentrations or tolerability for another. The existence of a common implant architecture therefore does not eliminate the need for product-specific development, manufacturing and clinical evidence.
The company’s licensed intellectual property may provide a foundation for protecting its technology, with Vinci reporting multiple granted patents covering EPIPLANT. Nevertheless, the announcement does not disclose sufficient information to assess the breadth, expiry dates or enforceability of individual claims. Patent ownership or licensing also does not establish that the platform will receive regulatory approval or achieve commercial adoption.
Vinci Pharmaceuticals has not disclosed a commercial licensing agreement involving VCI-002 or an established revenue stream from EPIPLANT products. Its immediate economic opportunity remains linked to advancing the technology sufficiently to attract additional financing, development partnerships or future clinical investment. As a privately held company, Vinci does not have a publicly traded share price through which to assess an investor reaction to the financing announcement.
What milestones will determine whether Vinci Pharmaceuticals can advance EPIPLANT into human testing?
The next measurable development will involve completion of the manufacturing and quality activities needed to support the planned VCI-002 study. Confirmation of the active ingredient, initial disease indication, dosing strategy and clinical trial design would provide a clearer assessment of the programme’s potential clinical relevance. A formally initiated study would then establish that the company had progressed beyond manufacturing preparations and preliminary preclinical development.
The initial clinical evidence will need to address two related but separate questions. The first is whether the episcleral implant can be administered with an acceptable safety and tolerability profile, while the second is whether it can maintain sufficient medicine exposure to produce a meaningful therapeutic effect in retinal tissues. Demonstrating both will be essential to establishing the credibility of the delivery approach.
If the first-in-human study produces encouraging results, larger controlled investigations would still be required to determine clinical efficacy and an appropriate long-term safety profile. Subsequent development would also need to clarify the frequency of implantation, the management of potential complications and the extent to which the product reduces conventional treatment requirements. Those outcomes will be necessary before claims about better adherence or lower healthcare costs can be substantiated.
The $8 million-plus Series A financing gives Vinci Pharmaceuticals resources to pursue a critical transition from preclinical development towards its first human investigation. EPIPLANT offers a distinct approach to sustained retinal drug delivery, particularly through its episcleral placement and bioerodible design, but its most important properties remain to be demonstrated clinically.
For the company, success in 2027 will not be measured simply by beginning a study. The more consequential milestone will be generating credible evidence that VCI-002 can deliver medication consistently, achieve appropriate retinal exposure and maintain an acceptable safety profile. Those findings will determine whether EPIPLANT has the potential to become a practical alternative to repeated intraocular drug administration and support a broader ophthalmic development programme.